← Return to Clinical trial (third line treatment) lurbinectedin and irinotecan

Discussion

Clinical trial (third line treatment) lurbinectedin and irinotecan

Pancreatic Cancer | Last Active: Jun 27, 2023 | Replies (29)
Comment receiving replies
@stageivsurvivor

(g)BRCA2.

Camille Moses did not have any detectable mutations in her PDAC tumor and is an exceptional responder. She is an 11 year survivor like me. I spoke on the phone with her last Friday. Was never eligible for surgery. Has a fully functioning, intact pancreas and takes no medications.

https://seenamagowitzfoundation.org/camille-moses-pancreatic-cancer-survivor/

Jump to this post

Replies to "(g)BRCA2. Camille Moses did not have any detectable mutations in her PDAC tumor and is an..."
gamaryanne | @gamaryanne | Jun 27, 2023

Thank you for sharing. I have not heard of this group before.
We have PANCAN, Lustgarden, and this foundation raising and directing funds to research. So you know of anymore?

VIEW AND REPLY